Selection of monoclonal antibodies for the development of a simple urinary test for bladder tumor detection

✍ Scribed by L. Lévesque; P. Douville; C. Parent; Y. Fradet

• Publisher: Elsevier Science
• Year: 1994
• Tongue: English
• Weight: 111 KB
• Volume: 27
• Category: Article
• ISSN: 0009-9120
• DOI: 10.1016/0009-9120(94)90065-5

✦ Synopsis

38TH ANNUAL CONFERENCE OF THE CANADIAN SOCIETY OF CLINICAL CHEMISTS diagnosis difficult on a clinical basis alone. Direct DNA genotyping at the FMR-1 locus has replaced classical cytogenetic testing for confirming the diagnosis as well as for carrier identification. DNA analysis methods are cumbersome and not suited for analysis of the FMR-I locus in all clinical situations where the syndrome is suspected. Recently, analysis of the fragile X protein was made possible by the production of antibodies to the gene product: pFMR-1. The antibodies detect a few protein bands in leukocytes of normal individuals and in transfected cell lines whereas in affected individuals, the FMR-1 protein is absent. Using a monoclonal antibody against pFMR-1, we tested its presence in human serum and plasma with the aim of developping an automated serologic test for diagnosis of fragile X syndrome. Using Western blotting, no FMR-l protein was detected in 13 normal human serum, 3 plasma and 3 whole blood samples. However, when leukocytes were isolated and tested separately, pFMR-l was detected. These results suggests that pFMR-1 is not present in whole blood, serum or plasma in a sufficient quantity in normal individuals to be detected by standard immunoassays. Ryan, E.D., and Bilous, G., Dept. of Clinical Chemistry, Room 2N46, McMaster Medical Centre,

COMPARISON OF CEA AND CA549 IN HUMAN BREAST TUMOUR TISSUE EXTRACTS